NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson, with support from the Johnson & Johnson (J&J) Foundation, announced that it has donated $100 million of MedTech products since 2020 to help more people around the world access the specialized care they need to live, see and smile. The Company has also planned to contribute an additional $20 million toward programs and impact investments that empower health workers to deliver cardiac, vision and surgical care in their communiti. ...

Core Insights - The artificial intelligence boom is gaining traction in the US and China, while Europe's role in AI markets may be undervalued, presenting new investment opportunities for 2026 [1] - AI's share of total European venture capital has increased to 27%, indicating a growing recognition of Europe's AI talent [1] Investment Landscape - The US has allocated 34% of its €1.33 trillion in VC funding to AI, while Europe has only allocated 18% of its €252 billion, highlighting a funding gap but also potential for growth in small-cap European AI stocks [2] - Concerns about a potential AI bubble in the US may lead investors to consider European stocks with calmer valuations and more resilient P/E ratios [3] Small-Cap European AI Stocks - **BE Semiconductor Industries (AMS: BESI)**: A major player in semiconductor manufacturing with a market cap of €12 billion, benefiting from high-end chip demand, particularly from Samsung [4][5] - **Indra Sistemas (BME: IDR)**: A Spanish defense firm expected to gain from AI integration and increased defense spending, with a stock rally of over 140% since early 2023 [6][7] - **STMicroelectronics (EPA: STMPA)**: A semiconductor stock with a market cap of €22 billion, recently secured a €1 billion deal to enhance competitiveness in AI [8][9] - **SUSS MicroTec (ETR: SMHN)**: The smallest on the list with a market cap of €850 million, specializing in lithography and microfabrication, has seen a stock increase of almost 190% since 2023 [10][11] - **Siemens Healthineers (OTC:SMMNY)**: A medical tech company with a market cap of around €52 billion, positioned to benefit from growing AI investments in healthcare [12][13] Market Outlook - European AI stocks present growth opportunities for investors seeking alternatives to high valuations in the US market, but thorough research is essential before investment [14] - Analysts are divided on the future of the AI industry, and any signs of strain in large-cap stocks could impact the growth of promising European companies [15]

Abbott Laboratories (ABT) shares snapped six straight sessions of losses, as the stock closed 1.2% higher at $108.77 on Monday. The MedTech giant started its downward trend on Jan. 15. The stock has lost over 13% in the preceding six sessions. ...

Core Insights - Avanos Medical (AVNS) and Siemens Healthineers have entered a strategic co-marketing agreement to enhance outpatient and interventional pain management by integrating advanced imaging with radiofrequency ablation (RFA) technologies [2][10] - The partnership reflects a trend of shifting complex pain procedures from hospitals to outpatient settings, focusing on flexible and cost-efficient solutions that improve clinical outcomes [3][8] Company Collaboration - The collaboration combines AVNS' RFA expertise with Siemens Healthineers' imaging technologies, aiming to improve procedural precision and broaden access to outpatient pain management solutions [4][5] - Siemens Healthineers' mobile C-arm systems, such as Cios Select and Cios Flow, will enhance imaging performance and support operational efficiency in pain management procedures [5][6] Strategic Implications - The agreement allows both companies to leverage existing strengths, enhancing AVNS' RFA portfolio and extending Siemens Healthineers' mobile C-arm systems into outpatient specialties [7] - The initial focus on the U.S. market, along with joint education and marketing initiatives, suggests a strategy aimed at accelerating adoption of these technologies [8] Industry Context - The pain management sector is witnessing strategic innovations from major MedTech players like Teleflex, Stryker, and Baxter, each pursuing unique approaches to meet evolving clinical needs [9] - Teleflex focuses on regional anesthesia solutions to enhance procedural safety and efficiency, while Stryker emphasizes minimally invasive outpatient solutions for spinal conditions [11][12] - Baxter offers ready-to-use formulations for local or regional anesthesia, streamlining administration and enhancing procedural efficiency [13]

Core Viewpoint - The Zacks Style Scores provide a framework for investors to evaluate stocks based on value, growth, and momentum, enhancing the decision-making process for stock selection [2][3][7]. Summary by Category Zacks Style Scores - The Zacks Style Scores rate stocks using a grading system from A to F, with A being the highest score indicating a better chance of outperforming the market [3]. - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6]. Value Score - The Value Score helps investors identify undervalued stocks by analyzing financial ratios such as P/E, PEG, Price/Sales, and Price/Cash Flow [3]. Growth Score - The Growth Score emphasizes a company's financial health and future growth potential, considering projected and historical earnings, sales, and cash flow [4]. Momentum Score - The Momentum Score assists investors in capitalizing on stock price trends, utilizing metrics like one-week price changes and monthly earnings estimate changes [5]. VGM Score - The VGM Score combines the three Style Scores to identify stocks with attractive value, strong growth forecasts, and promising momentum, serving as a useful indicator alongside the Zacks Rank [6]. Zacks Rank - The Zacks Rank is a proprietary model that leverages earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks achieving an average annual return of +23.83% since 1988, significantly outperforming the S&P 500 [7][8]. Stock Example: Stryker (SYK) - Stryker is a leading medical technology company, generating approximately 60% of its sales from MedSurg & Neurotechnology and 40% from Orthopaedics, with about 75% of revenue coming from the U.S. market [12]. - Stryker holds a 3 (Hold) rating on the Zacks Rank and has a VGM Score of B, with a Momentum Style Score of B, indicating potential for investors [13][14].

Core Viewpoint - Abbott Laboratories experienced a significant drop in share price following its Q4 2025 earnings report, which revealed lower-than-expected revenue, leading to concerns among investors about the company's performance and future growth prospects [1]. Group 1: Financial Performance - Abbott reported Q4 revenue of $11.5 billion, missing Wall Street's expectation of $11.8 billion, primarily due to challenges in its nutrition segment [3]. - Despite the revenue miss, Abbott's adjusted diluted earnings per share (EPS) increased by 12% year over year, aligning with analysts' estimates [3]. - The company anticipates overall revenue growth to accelerate in 2026, projecting organic sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.55 to $5.80, indicating a 10% year-over-year growth at the midpoint [4]. Group 2: Market Position and Future Outlook - Abbott is recognized as a Dividend King, having increased its dividend for 54 consecutive years, making it an attractive option for income investors [2]. - The company is expected to implement changes in its nutrition business to drive a return to growth in the second half of 2026 [3]. - Abbott's diversified business model and comprehensive product portfolio position it favorably within the medtech and diagnostics markets, as stated by CEO Robert Ford [6].

近日，广东省科学技术厅正式公布2025年度广东省工程技术研究中心认定名单，由汕头大学医学院附属 深圳妇儿医院（深圳市龙岗区妇幼保健院，简称"龙岗妇幼"）牵头，联合中山大学公共卫生学院（深 圳）、深圳赛陆医疗科技有限公司共建的"广东省基因遗传组学与精准影像工程技术研究中心"成功获 批，标志着龙岗妇幼在出生缺陷防控、精准医学领域的创新实践正式纳入省级战略平台，为区域妇幼健 康事业高质量发展注入强劲动力。 据了解，此次获批是龙岗妇幼向高水平临床研究型妇幼保健机构迈进的里程碑，也是龙岗区在精准医学 交叉领域的重大突破。当前，出生缺陷防控是提升人口素质的核心环节，而基因诊断与影像评估技术存 在天然壁垒——基因层面难以直观关联胎儿宏观表型，影像层面无法揭示深层遗传病因，形成"基因型- 表型关联断裂"的行业痛点。 作为深圳东部唯一的产前诊断中心，龙岗妇幼已构建起"三平台四实验室"科研体系，凭借高通量基因测 序、染色体核型分析等先进技术及精准超声筛查手段，每年为近3万名孕妇提供遗传咨询与产前诊断服 务。近三年来，成功干预400余例严重出生缺陷妊娠，开展胎儿宫内治疗90余例，筑牢出生缺陷防控防 线，为省级工程技术研究中心的建设 ...

Core Insights - Healthcare stocks experienced a rally in 2025, breaking a two-year slump as investors sought steadier rates, better valuations, and improving earnings, although mid-single-digit gains still lagged behind tech stocks [2][6] - Investors are shifting focus from high-risk biotech to MedTech and healthcare services, which are based on procedure volume and recurring revenue, reducing exposure to binary risks associated with drug development [3][6] Company Highlights - Johnson & Johnson (J&J) has shifted its focus to innovative medicine and medical technology after spinning off its consumer products division, with MedTech sales increasing by 6.1% to $33.8 billion in 2025, including $8.8 billion in the fourth quarter [4][5] - Intuitive Surgical is highlighted as a strong growth story in healthcare, benefiting from rising global procedure volumes and a business model that generates recurring revenue from instruments and services used in surgeries [5][7] - Other companies like Edwards Lifesciences and IQVIA are also positioned to capitalize on growth opportunities in the healthcare sector, indicating a broader trend beyond traditional biotech [6]

Core Insights - The article highlights the top-performing analysts in the U.S. for the year 2025, as ranked by TipRanks based on their success rates and average returns [1][2]. Analyst Rankings - **Sam Slutsky – LifeSci Capital**: Achieved the highest ranking with a success rate of 67.74% and an average return of 62.4%. His notable recommendation on Abivax SA (ABVX) yielded a return of 894.81% [3]. - **Richard Shannon – Craig-Hallum**: Ranked second with a success rate of 61.87% and an average return of 36.9%. His top call on Aeva Technologies (AEVA) generated a return of 822.14% [4]. - **Joseph Stringer – Needham**: Secured the third position with a success rate of 79.17% and an average return of 38.2%. His best recommendation was for Inozyme Pharma (INZY), which returned 361.9% [5]. - **Myles Minter – William Blair**: Fourth place with a success rate of 66.93% and an average return of 28.8%. His top recommendation on Ovid Therapeutics (OVID) yielded a profit of 350% [6]. - **Ruben Roy – Stifel Nicolaus**: Fifth on the list with a success rate of 75.68% and an average return of 35.3%. His best call on CoreWeave (CRWV) generated a return of 293.2% [7]. - **Seamus Fernandez – Guggenheim**: Ranked sixth with a success rate of 78.57% and an average return of 40.6%. His best recommendation was for Cidara Therapeutics (CDTX), which returned 244.7% [8]. - **Thomas Smith – Leerink Partners**: Seventh place with an average return of 30.7% and a success rate of 65.22%. His best recommendation on Abivax yielded a return of 880.34% [9]. - **Mark Miller – Benchmark Co.**: Eighth with a success rate of 59.8% and an average return of 11.1%. His top call on SanDisk (SNDK) generated a return of 470.6% [11]. - **Allison Bratzel – Piper Sandler**: Ninth position with a success rate of 63.64% and an average return of 58.2%. His recommendation for Abivax also yielded a return of 894.81% [12]. - **Julian Harrison – BTIG**: Tenth with a success rate of 59.38% and an average return of 37%. His top recommendation on Abivax generated a return of 1,057.12% [13].

Core Viewpoint - TELA Bio, Inc. has approved inducement grants of restricted stock units to five newly-hired employees as part of their employment compensation, aimed at enhancing talent acquisition and retention [1]. Group 1: Inducement Grants - The Compensation Committee of TELA Bio's Board of Directors approved grants covering 14,250 shares of common stock to five new employees, with a grant date of January 20, 2026 [1]. - The restricted stock units will vest in equal annual installments over four years, contingent on the employees' continued service with TELA Bio [2]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that prioritize the preservation and restoration of the patient's own anatomy [3]. - The company aims to provide advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials [3].